NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free NLSP Stock Alerts $0.14 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.3752-Week Range$0.11▼$1.53Volume36,940 shsAverage Volume173,811 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NLS Pharmaceutics alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About NLS Pharmaceutics Stock (NASDAQ:NLSP)NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More NLSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLSP Stock News HeadlinesMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 14, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 11, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceMarch 11, 2024 | finance.yahoo.comNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing ComplianceFebruary 23, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 14, 2024 | seekingalpha.comNLSP NLS Pharmaceutics Ltd.January 20, 2024 | finance.yahoo.comNotice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 12, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing RequirementsDecember 23, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider TradesDecember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary SharesDecember 5, 2023 | benzinga.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and DatesDecember 1, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.November 27, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaNovember 21, 2023 | morningstar.comNLS Pharmaceutics Ltd Ordinary Shares NLSPNovember 16, 2023 | msn.comWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% TodayNovember 16, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanOctober 19, 2023 | finance.yahoo.comNLS Pharmaceuticals to Reschedule Company Update on Strategic DiscussionsOctober 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 5, 2023 | msn.comNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95September 14, 2023 | msn.comMaxim Group Downgrades NLS Pharmaceutics (NLSP)August 28, 2023 | benzinga.comNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder LetterJuly 3, 2023 | finance.yahoo.comNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study ProtocolSee More Headlines Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book0.50Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.70 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Alexander Zwyer M.B.A. (Age 55)President, CEO & Director Comp: $1.07MDr. George Apostol M.D. (Age 51)Chief Medical Officer and Global Head of Research & Development Comp: $154kDr. Eric Konofal M.D. (Age 57)Ph.D., Co-Founder & Chief Scientific Officer Ms. Elena Thyen-PighinChief Financial OfficerDr. Christian C. Wenger Dr. iur. (Age 60)L.L.M., Ph.D., General Counsel Key CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZPharvarisNASDAQ:PHVSView All Competitors NLSP Stock Analysis - Frequently Asked Questions Should I buy or sell NLS Pharmaceutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLSP, but not buy additional shares or sell existing shares. View NLSP analyst ratings or view top-rated stocks. How have NLSP shares performed in 2024? NLS Pharmaceutics' stock was trading at $0.5899 on January 1st, 2024. Since then, NLSP shares have decreased by 76.4% and is now trading at $0.1393. View the best growth stocks for 2024 here. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NLSP) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
